Solventum Corporation $SOLV Shares Sold by Ieq Capital LLC

Ieq Capital LLC reduced its holdings in Solventum Corporation (NYSE:SOLV) by 77.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,515 shares of the company’s stock after selling 15,160 shares during the period. Ieq Capital LLC’s holdings in Solventum were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Ameriprise Financial Inc. raised its stake in Solventum by 14.8% during the fourth quarter. Ameriprise Financial Inc. now owns 75,874 shares of the company’s stock worth $5,023,000 after purchasing an additional 9,776 shares during the period. BNP Paribas Financial Markets raised its stake in Solventum by 39.2% during the fourth quarter. BNP Paribas Financial Markets now owns 244,699 shares of the company’s stock worth $16,165,000 after purchasing an additional 68,916 shares during the period. Bank of America Corp DE raised its stake in Solventum by 5.1% during the fourth quarter. Bank of America Corp DE now owns 855,690 shares of the company’s stock worth $56,527,000 after purchasing an additional 41,578 shares during the period. Captrust Financial Advisors raised its stake in Solventum by 43.2% during the fourth quarter. Captrust Financial Advisors now owns 35,165 shares of the company’s stock worth $2,323,000 after purchasing an additional 10,611 shares during the period. Finally, Colonial Trust Co SC raised its stake in Solventum by 240.7% during the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company’s stock worth $34,000 after purchasing an additional 361 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SOLV. Wall Street Zen upgraded shares of Solventum from a “buy” rating to a “strong-buy” rating in a research report on Monday, September 1st. KeyCorp began coverage on shares of Solventum in a research report on Friday, June 6th. They set a “sector weight” rating for the company. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Piper Sandler reiterated an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and an average target price of $85.75.

Solventum Trading Up 0.4%

NYSE SOLV opened at $72.70 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The stock has a market capitalization of $12.61 billion, a PE ratio of 33.66, a price-to-earnings-growth ratio of 1.75 and a beta of 0.53. The firm has a 50 day moving average of $73.53 and a two-hundred day moving average of $72.77.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter in the previous year, the business posted $1.56 EPS. The firm’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.